Full Press Release Details
("Midatech" or the "Company")
Result of 2020 Annual General Meeting
Midatech Pharma PLC (AIM: MTPH.L;
Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces
that at its Annual General Meeting (AGM) held at 11.30am today, with the exception of resolutions 6 (disapplication of pre-emption
rights) and 7 (authority to purchase own shares) which failed to carry, all other resolutions put to the meeting were duly
passed by shareholders by way of a poll.
With respect to resolution 6,
365,845 votes were cast for and 976,164 votes were cast against, representing 0.9% and 2.5% of eligible votes respectively. With
respect to resolution 7, 515,216 votes were cast for and 858,043 were cast against, representing 1.3% and 2.2% of eligible votes
The UK Placing, which was
announced on 27 July 2020, is not affected by the outcome of the voting above on the basis that allotment of the Placing
Shares and Broker Option Shares has been made pursuant to existing share authorities which the Directors were given at the Company's
General Meeting held on 2 March 2020.
Unless otherwise stated,
capitalised terms used in this announcement have the meanings given to them in the announcement of the UK Placing on 27 July 2020.
For more information,
(UK) Limited (Nominated Adviser and Joint Broker)
Emma Earl (Corporate Finance)
Investments (TPI) Limited (Joint Broker, Sole Bookrunner)
Andrew Thacker (Corporate Broking)
Tel: +44(0)20 3657 0050
Limited (Financial PR and UK Investor Relations)
Edison Group (US Investor Relations)
Megan Paul / Laine Yonker
Tel: (646) 653-7030/ 7035
Midatech Pharma PLC (dual listed on LSE
AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on Making Medicines Better' by improving delivery of drugs
in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide
compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment
for life threatening diseases.
The Company has developed three in-house
technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's
technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:
By improving bio-delivery and biodistribution
of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks,
accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies
allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.
Midatech's technologies are supported
by 36 patent families including 120 granted patents and an additional 70 patent applications.
Midatech's headquarters and R&D facility
is in Cardiff, UK. For more information please visit www.midatechpharma.com